Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product candidate VP-102, is a proprietary topical therapy used in common skin indications including molluscum contagiosum and verruca vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Verrica Pharmaceuticals reports strong Q3 revenue growth and promising therapies

Verrica Pharmaceuticals' Q3 performance reflects strong revenue generation from YCANTH and promising developments in novel therapies like VP-315.
While facing challenges in market clearance efforts and significant SG&A costs, the company's strategic initiatives position it for future growth.
Opportunities lie in expanding market presence, optimizing costs, and protecting intellectual property to drive profitability and innovation.

Verrica Pharmaceuticals reports robust Q4 earnings and eyes regulatory milestones

Verrica Pharmaceuticals showcased strong financial performance with $1.9 million in YCANTH net revenue and 94% gross margins for 2023.
Strategic partnerships, pipeline advancements, and progress in eliminating market challenges position the company for future growth.
Challenges in sampling activity, revenue forecasting, and regulatory uncertainties require careful navigation for sustained success.
Opportunities in distribution expansion, revenue optimization, and regulatory advancements offer avenues for continued development and success.

Verrica Pharmaceuticals excels in Q1 with strong revenue growth

Verrica Pharmaceuticals demonstrated strong performance in Q1 2024 with significant revenue generation and pipeline advancements.
While facing financial challenges and uncertainties, the company's strategic strengths and opportunities position it well for future growth.
Addressing cost management, market integrity, and maximizing revenue potential will be crucial for sustaining profitability and market leadership.

Verrica Pharmaceuticals excels in Q2, eyes market expansion opportunities

Verrica Pharmaceuticals' Q2 performance reflects strong revenue growth and promising developments in product pipelines. While challenges exist in accelerating demand and maintaining profitability, the company's strategic focus on partnerships and market optimization positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance Presentation to highlight the antitumor efficacy of VP-315 for the Treatment of Basal Cell Carcinoma (BCC) as determined by clinical and histological lesion clearance

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's (AAD) 2023 Innovation Academy Meeting

– Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of certain revenue milestones –

Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed

Verrica focuses on dermatology therapeutics. The company just received approval for its first marketed product.

Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday

WEST CHESTER, Pa., July 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company has entered into a non-binding term sheet for a term loan facility of up to $125 million, which the Company expects to close by the end of this week.

Following FDA Approval of YCANTH™ for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET

The U.S. Food and Drug Administration has approved Verrica Pharmaceuticals Inc's treatment of a viral skin disease in adults and children aged 2 years and above, the company said on Friday.

US FDA approves Verrica's skin disease treatment

– Molluscum, is a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children –

Verrica Pharmaceuticals Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

WEST CHESTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Healthcare Conference, which is being held at the New York Marriot Marquis from June 7-9, 2023.

Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York

WEST CHESTER, Pa., May 10, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held at the InterContinental New York Barclay Hotel from May 16-17, 2023.

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

OmniAb Inc

Point Biopharma Global

Adicet Bio, Inc.

AC Immune

Altimmune

CorMedix

Standing among the most compelling opportunities, biotech stocks to buy and hold also present high risks. Unlike other sectors, companies can't just introduce health-related products directly to the market.

7 Biotech Stocks With Huge Return Potential for Long-Term Investors

WEST CHESTER, Pa., April 12, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or, the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the first patient has been dosed in Part 2 of a Phase 2 study evaluating the Company's potentially first-in-class oncolytic peptide, VP-315, for the treatment of basal cell carcinoma. Part 2 of the Phase 2 trial is designed to further explore dosing regimens to identify the recommended dose for Part 3 of the study, which is expected to start in the first half of 2024.

Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma

WEST CHESTER, Pa., April 11, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will present at the 22nd Annual Needham Virtual Healthcare Conference, which is being held from April 17-20, 2023.

Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference

New Drug Application for VP-102 assigned PDUFA goal date of July 23, 2023

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results

WEST CHESTER, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President and CEO, will participate in a fireside chat at The Cowen 43rd Annual Health Care Conference, taking place from March 6 - 8, 2023, in Boston, MA.

Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference

Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum

WEST CHESTER, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten offering of 750,000 shares of its common stock and pre-funded warrants to purchase 4,064,814 shares of common stock. The shares of common stock are being sold at a price of $6.75 per share and the pre-funded warrants are being sold at a price of $6.7499 per share.  The offering is being substantially led by one healthcare dedicated fund. The gross proceeds from the offering to Verrica are expected to be approximately $32.5 million, before deducting underwriting discounts and commissions and offering expenses. The offering is expected to close on or about February 23, 2023, subject to customary closing conditions.

Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Registration Stability Batch for VP-102 Completed and Placed on Stability

Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions

Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023

Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results

WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 3:30 p.m. ET.

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference

Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum

Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results

NEW YORK , Aug. 5, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/verrica-pharmaceuticals-inc-loss-submission- form/?id=30554&from=4 The lawsuit seeks to recover losses for shareholders who purchased Verrica between May 28, 2021 and May 24, 2022.

VRCA SHAREHOLDER ALERT: Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

New York, New York--(Newsfile Corp. - August 5, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) between May 28, 2021 and May 24, 2022, both dates inclusive (the "Class Period"), of the important August 5, 2022 lead plaintiff deadline.

VRCA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Verrica Pharmaceuticals Inc. Investors to Secure Counsel Before Important August 5 Deadline in Securities Class Action - VRCA

Los Angeles, California--(Newsfile Corp. - August 5, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Verrica Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 5, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (NASDAQ: VRCA) securities between May 28, 2021 and May 24, 2022, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In December 2020, Verrica submitted its New Drug Applica

News for Verrica Pharmaceuticals Inc Stock (VRCA)